For citations:

Kolbin A.S., Vilum I.A., Balykina Yu.E., Proskurin M.A. Pharmacoeconomic analysis of the use of ibrutinib in therapy of the first line of a chronic lymphocytic leukaemia for patients with 17p deletion. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2015;(1):32-43. (In Russ.)